By Denny Jacob

Moderna Inc. shares rose 5.7% to $128.53 in late trading Wednesday after The Wall Street Journal reported that the company is planning to test its Covid-19 vaccine in babies 3 months to 6 months old, the youngest age group studied to date.

The company said it is in the final stages of planning the study, to be called BabyCove and expected to begin enrolling as many as 700 babies in September, the Journal said. BabyCove would be the first study of Moderna's vaccine in infants younger than 6 months, the Journal said.

Separately on Wednesday, health experts advising U.S. health regulators backed giving vaccines from Pfizer Inc. and BioNTech SE and from Moderna to children as young as six months old. This will likely lead to an expansion of the vaccination campaign in the U.S. to the 19.6 million children 6 months to under 5 years of age, one of the last groups waiting for the shots.

The Food and Drug Administration, which doesn't have to follow the panel's recommendations but usually does, is expected to authorize the shots within days.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

June 15, 2022 16:20 ET (20:20 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Moderna.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Moderna.